06.11.08	Targeted Anticancer Drugs - In Vitro Assessment and Non-Invasive Imaging of Patient and Tumor Status Will Determine Clinical and Commercial Success
03.26.08	Diagnostics, Theragnostics, Prognostics, Pharmacogenomics and Biomarkers in Oncology Numerous Commercial and Academic Groups are Developing Products/Technologies that Will Play a Critical Role in Clinical Trial Design and Patient Selection and Treatment Assessment, and May Determine the Future Success of Anticancer Drugs
02.19.08	Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
11.27.07	Anticancer Drugs Targeting the ErbB (EGFr/HEr2) Pathway Alone Generated Global Sales of nearly $5 billion in the First Nine Months of 2007
09.18.07	Oncology Drugs Development Update - Worldwide Markets and Forecasts of Approved EGFr/HEr2 Inhibitors, Treatment Costs, Pathway Analysis, Current and Expanded Clinical Indications, and Novel Agents in Development
07.17.07	Oncology Drug Development-Mid-Year 2007 Update
05.29.07	Oncology Drug Development Update Targeted Drugs from the 2007 Meeting of the American Association of Cancer Research (AACR)
04.03.07	Oncology Drug Development Update EGFr-Targeted Drugs: Vectibix Setback, EGFr Testing
03.27.07	Oncology Drug Development Information Resources
01.09.07	Oncology Drug Development Information Resources
10.09.06	Oncology Drug Development Update Targeting the Epidermal Growth Factor Receptor (EGFr) Signal Transduction Pathway
07.12.06	Oncology Drug Development Update Over 600 Novel Anticancer Agents in Development were Added/Updated in New Medicine's Oncology KnowledgeBASE (nm|OK) in the first 6 months of 2006, Including Over 190 Agents in Clinical Development Targeting over 154 Distinct Molecular Markers
02.07.06	Oncology Drug Development Update Monotherapy Phase I Clinical Trials of Novel Cytotoxics, Targeted Therapeutics, Antimetastatic Agents/Angiogenesis Inhibitors, and Immunotherapeutics/Vaccines
11.30.05	Oncology Drug Development Update Monotherapy Phase I Clinical Trials of Novel Drugs/Formulations-Novel Cytotoxics, Targeted Therapeutics, Antimetastatic Agents/Angiogenesis Inhibitors, and Immunotherapy/Vaccines
10.10.05	Oncology Drug Development Update Over 988 New Drugs were Added/Updated in the First Nine Months of 2005, from a Pool of Over 3,000 Agents Incorporated in New Medicine's Oncology KnowledgeBASE (nm|OK) In Addition 244 Targets were Added/Updated as well as 410 Combination Trials of Recently Approved Anticancer Agents
07.19.05	Oncology Drug Development: the c-SRC Signaling Pathway
05.03.05	Oncology Drug Development Update-Over 545 New Drugs were Added/Updated in the First Four Months of 2005, from a Pool of Over 3,000 Agents Incorporated in New Medicine's Oncology KnowledgeBASE (nm|OK)
04.26.05	Update on Pancreatic Cancer Epidemiology · Molecular Markers · Prognosis, Diagnosis and Disease Monitoring · State-of-the-Art Treatments · Novel Cytotoxics, Targeted Therapeutics, Antimetastatic Agents, and Immunotherapy/Vaccines
02.16.05	Oncology Drug Development Update - Over 142 Records of Novel Drugs Were Added/Updated in January 2005 from a Pool of Over 3,000 Agents Incorporated in New Medicine's Oncology KnowledgeBASE (nm|OK)
07.08.04	Oncology Drug Development Update June 2004
09.16.03	Oncology KnowledgeBASE Update - Hundreds of Novel Agents Targeting a Multitude of Newly Discovered Markers Have Entered Clinical Trials
04.30.03	Anticancer Agents From Antibiotic Sources - New Antibiotics, Analogs and Derivatives, and Targeted Cytotoxics - a Report From New Medicine
11.05.02	Oncology KnowledgeBASE Update - Hundreds of Novel Agents Targeting a Multitude of Newly Discovered Markers Have Entered Clinical Trials
9.18.02	Update on Spindle Poisons-Taxanes, Vinca Alkaloids and Novel Anticancer Drugs Acting by Disrupting the Cytoskeleton of Tumor Cells
8.07.02	Oncology Drug Development Update
06.26.02	Numerous Novel Anticancer Agents Are in Early-Stage of Clinical Development
06.05.02	New Strategies Regarding Combination Therapies, Target Validation and Chemoprevention Taking Center Stage in Cancer Drug Development
3.12.02	Future Oncology Issues a Comprehensive Report on Clinical and Market Developments in the Taxane Group of Spindle Poisons
11.05.01	New Medicine posted estimates of global markets for anticancer agents and adjuncts on its subscription-based oncologyknowledgebase.com website
7.10.01	Over 300 Clinical Trials Involving More Than 100 Anticancer Agents Acting By Regulatory Rather Than Cytotoxic Mechanisms Have Been Initiated According to New Medicine's Oncology KnowledgeBASE (nm/OK) Commercialization of These Agents as Monotherapies and/or Combination Therapies Will Revolutionize the Way Cancer is Treated
3.20.01	Over 547 Anticancer Drugs Based on Novel Mechanisms Are in Development With Many in Late-Stage Clinical Trials, According to Oncology KnowledgeBASE Commercialization of These Agents Will Revolutionize the Way Cancer Is Treated
11.08.00	Over 1,500 Anticancer Agents are in Active Development, With 522 in Clinical Trials, According to Web-Based New Medicine's Oncology KnowledgeBASE (nm/OK)
9.27.00	Future Oncology Publishes A Comprehensive Review of Lung Cancer Comprising WorldWide Epidemiology, Current Treatment Approaches, Novel Agents In Development, And Market Opportunities
12.07.99	Future Oncology Publishes A Comprehensive Review Of Markets Of Oncology Drugs
8.03.99	New Medicine Issues A Comprehensive Report On Worldwide Product Development And Market Opportunities In The Management Of Moderate-To-Severe Pain With Special Emphasis On Cancer-Related Pain
6.01.99	Demo of New Medicine’s Comprehensive Oncology Knowledgebase Now On The Company’s Web Site
10.07.98	Future Oncology Publishes A Comprehensive Review Of Prostate Cancer And Identifies Over 180 Separate Products In Development To Treat This Disease